{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:49:28Z","timestamp":1791668968327,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005015","name":"South China University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computer Methods and Programs in Biomedicine"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cmpb.2026.109679","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:33:27Z","timestamp":1791318807000},"page":"109679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Daidzein derivatives as potential inhibitors of mutant EGFR in non-small cell lung cancer: A computational study supported by molecular docking, DFT, molecular dynamics simulations, and MM\/PBSA techniques"],"prefix":"10.1016","volume":"288","author":[{"given":"Fatima","family":"Munir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6628-8989","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmpb.2026.109679_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cmpb.2026.109679_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215459","article-title":"Copper pyrazole complexes as potential anticancer agents: evaluation of cytotoxic response against cancer cells and their mechanistic action at the molecular level","volume":"498","author":"Ghorbanpour","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.cmpb.2026.109679_bib0003","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cmpb.2026.109679_bib0004","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.3390\/cancers15184525","article-title":"Environmental toxicants exposure, and lung cancer risk","volume":"15","author":"Shehata","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cmpb.2026.109679_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202400448","article-title":"EAT-Lancet diet pattern, genetic predisposition, inflammatory biomarkers, and risk of lung cancer incidence and mortality","volume":"68","author":"Liu","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.cmpb.2026.109679_bib0006","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.cmpb.2026.109679_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC \u2014 Mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cmpb.2026.109679_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2025.109052","article-title":"Identification of novel inhibitors targeting EGFR L858R\/T790M\/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches","volume":"138","author":"Wei","year":"2025","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.cmpb.2026.109679_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102628","article-title":"A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments","volume":"120","author":"Zwierenga","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cmpb.2026.109679_bib0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.cmpb.2026.109679_bib0011","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of Gefitinib for the treatment of patients with metastatic EGFR mutation\u2013Positive non\u2013Small cell lung cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmpb.2026.109679_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108057","article-title":"Derivatives of D(\u2212)-glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-III: synthesis, biological screening and in silico binding interaction analysis","volume":"154","author":"Das","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116563","article-title":"Derivatives of D(\u2212) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-part-I: synthesis, biological screening and in silico binding interaction analysis","volume":"274","author":"Das","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.02.061","article-title":"Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors","volume":"130","author":"Zheng","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs","volume":"93","author":"Fabbro","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cmpb.2026.109679_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104274","article-title":"Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)","volume":"105","author":"Shaheen","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136021","article-title":"Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors","volume":"1291","author":"Pal","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.cmpb.2026.109679_bib0018","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"8","author":"Andrews Wright","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.cmpb.2026.109679_bib0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/1568011023353949","article-title":"Cytotoxic anticancer candidates from natural resources","volume":"2","author":"Kim","year":"2002","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.cmpb.2026.109679_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/efd2.70008","article-title":"A review on daidzein as food supplement: exploring its phytopharmacological and preclinical status","volume":"5","author":"Ahmad","year":"2024","journal-title":"EFood"},{"key":"10.1016\/j.cmpb.2026.109679_bib0021","doi-asserted-by":"crossref","first-page":"117","DOI":"10.21010\/ajtcam.v13i3.15","article-title":"Daidzein: a review of pharmacological effects","volume":"13","author":"Sun","year":"2016","journal-title":"Afr. J. Tradit. Complement. Altern. Med."},{"key":"10.1016\/j.cmpb.2026.109679_bib0022","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2174\/0113816128330530240918073721","article-title":"Daidzein inhibits non-small cell lung cancer growth by pyroptosis","volume":"31","author":"Zeng","year":"2025","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cmpb.2026.109679_bib0023","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3892\/ol.2021.13050","article-title":"Microarray analysis of differentially expressed long non-coding RNAs in daidzein-treated lung cancer cells","volume":"22","author":"Li","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cmpb.2026.109679_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2020.03.004","article-title":"Daidzein-rich isoflavones aglycone inhibits lung cancer growth through inhibition of NF-\u03bab signaling pathway","volume":"222","author":"Guo","year":"2020","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.cmpb.2026.109679_bib0025","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1021\/acs.jmedchem.6b01894","article-title":"Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutant\u2026","volume":"60","author":"Planken","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.cmpb.2026.109679_bib0027","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmpb.2026.109679_bib0028","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1021\/acs.jmedchem.6b01894","article-title":"Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutant\u2026","volume":"60","author":"Planken","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0029","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"\u0160ali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.cmpb.2026.109679_bib0030","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0031","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0032","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6446(01)01712-3","article-title":"Screening for human ADME\/tox drug properties in drug discovery","volume":"6","author":"Li","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cmpb.2026.109679_bib0033","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3762\/bjoc.12.267","article-title":"Computational methods in drug discovery","volume":"12","author":"Leelananda","year":"2016","journal-title":"Beilstein. J. Org. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0034","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1134\/S1068162022050168","article-title":"SwissADME predictions of drug-likeness of 5-nitro imidazole derivatives as potential antimicrobial and antifungal agents","volume":"48","author":"Pattanayak","year":"2022","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.132285","article-title":"Computational investigation of bioactive 2,3-diaryl quinolines using DFT method: FT- IR, NMR spectra, NBO, NLO, HOMO-LUMO transitions, and quantum-chemical properties","volume":"1253","author":"Janeoo","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.cmpb.2026.109679_bib0035","doi-asserted-by":"crossref","unstructured":"Y. Sheena Mary, C. Yohannan Panicker, M. Sapnakumari, B. Narayana, B.K. Sarojini, A.A. Al-Saadi, C. Van Alsenoy, J.A.J S. acta. P.A. War Molecular, Biomolecular spectroscopy, molecular structure, FT-IR, vibrational assignments, HOMO-LUMO, MEP, NBO analysis and molecular docking study of ethyl-6-(4-chlorophenyl)-4-(4-fluorophenyl)-2-oxocyclohex-3-ene-1-carboxylate, 138 (2015) 73\u201384.","DOI":"10.1016\/j.saa.2014.11.012"},{"key":"10.1016\/j.cmpb.2026.109679_bib0037","unstructured":"G. Al-Dahash, H. Abbood, G.H. Int. J.C., Undefined 2016, Theoretical study of geometry optimization and energies for donor-\u03c0 bridge-acceptor molecular system: B3LYP\/DFT calculations, (n.d.)."},{"key":"10.1016\/j.cmpb.2026.109679_bib0038","volume":"20","author":"Dennington","year":"2008"},{"key":"10.1016\/j.cmpb.2026.109679_bib0039","doi-asserted-by":"crossref","unstructured":"M.J. Abraham, T. Murtola, R. Schulz, S. P\u00e1ll, J.C. Smith, B. Hess, E.J.S. Lindahl, GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers, 1 (2015) 19\u201325.","DOI":"10.1016\/j.softx.2015.06.001"},{"key":"10.1016\/j.cmpb.2026.109679_bib0040","doi-asserted-by":"crossref","DOI":"10.1063\/1.4960175","article-title":"Accuracy limit of rigid 3-point water models","volume":"145","author":"Izadi","year":"2016","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.cmpb.2026.109679_bib0041","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.cmpb.2026.109679_bib0042","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0043","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE - AnteChamber PYthon Parser interfacE","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.cmpb.2026.109679_bib0044","doi-asserted-by":"crossref","DOI":"10.1063\/1.3693330","article-title":"Ionic force field optimization based on single-ion and ion-pair solvation properties: going beyond standard mixing rules","volume":"136","author":"Fyta","year":"2012","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.cmpb.2026.109679_bib0045","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.265.5176.1219","article-title":"The spatial structure in liquid water","volume":"265","author":"Kusalik","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.cmpb.2026.109679_bib0046","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1021\/acs.jpcb.7b11734","article-title":"Biomolecular simulations under realistic macroscopic salt conditions","volume":"122","author":"Ross","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.cmpb.2026.109679_bib0047","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-LINCS: a parallel linear constraint solver for molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.cmpb.2026.109679_bib0048","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.cmpb.2026.109679_bib0049","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.cmpb.2026.109679_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.132332","article-title":"Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis","volume":"270","author":"Ahmad","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cmpb.2026.109679_bib0051","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1039\/C5TC02385H","article-title":"Rational design of diketopyrrolopyrrole-based oligomers with deep HOMO level and tunable liquid crystal behavior by modulating the sequence and strength of the donor moiety","volume":"3","author":"Wang","year":"2015","journal-title":"J. Mater. Chem. C Mater."},{"key":"10.1016\/j.cmpb.2026.109679_bib0052","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wcms.19","article-title":"The electrostatic potential: an overview","volume":"1","author":"Murray","year":"2011","journal-title":"WIREs Comput. Mol. Sci."},{"key":"10.1016\/j.cmpb.2026.109679_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/srep34984","article-title":"Structural insights into conformational stability of both wild-type and mutant EZH2 receptor","volume":"6","author":"Aier","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmpb.2026.109679_bib0054","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.cmpb.2026.109679_bib0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cmpb.2026.109679_bib0056","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/prot.23225","article-title":"Longer simulations sample larger subspaces of conformations while maintaining robust mechanisms of motion","volume":"80","author":"Liu","year":"2012","journal-title":"Proteins"},{"key":"10.1016\/j.cmpb.2026.109679_bib0057","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/07391102.2023.2291174","article-title":"Investigating the multitargeted anti-diabetic potential of cucurbitane-type triterpenoid from Momordica charantia: an LC-MS, docking-based MM\\GBSA and MD simulation study","volume":"43","author":"Famuyiwa","year":"2025","journal-title":"J. Biomol. Struct. Dyn."}],"container-title":["Computer Methods and Programs in Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260726004281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169260726004281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:18:34Z","timestamp":1791667114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169260726004281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":57,"alternative-id":["S0169260726004281"],"URL":"https:\/\/doi.org\/10.1016\/j.cmpb.2026.109679","relation":{},"ISSN":["0169-2607"],"issn-type":[{"value":"0169-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daidzein derivatives as potential inhibitors of mutant EGFR in non-small cell lung cancer: A computational study supported by molecular docking, DFT, molecular dynamics simulations, and MM\/PBSA techniques","name":"articletitle","label":"Article Title"},{"value":"Computer Methods and Programs in Biomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmpb.2026.109679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109679"}}